hAAT Inhibited Antibody Production and Proteinuria in NZM2410 Mice
8-week-old female NZM2410 mice (N = 10) were treated with PBS, AAT, or rAAV8-CB-hAAT and sacrificed at 22 weeks of age. (A) Serum hAAT levels in the AAT protein-treated group. The dashed line shows the lower limit of quantification (LLOQ). Results from the PBS-treated group were below LLOQ and are not shown. (B) Serum hAAT levels in the rAAV8-CB-hAAT-treated group. (C) Serum anti-hAAT IgG levels in the hAAT- and rAAV8-CB-hAAT-treated groups. Results from the PBS-treated group were below LLOQ. (D) Serum anti-dsDNA IgG levels at 8 (prior treatments), 16, 17, 18, 19, 20, and 21 weeks of age were detected by ELISA. The area under the curve (AUC) for each animal was calculated, and the average of AUC for each group was plotted and analyzed (E and F) Serum levels of total IgM (E) and IgG (F) at 22 weeks of age. Data were expressed as the mean ± SEM and analyzed by one-way ANOVA using Tukey’s post hoc test corrections. (G–I) Detectable levels of urine albumin (G), IL-12 (H), and IFN-γ (I) levels at 22 weeks of age. PBS versus rAAV-CB-hAAT was expressed as the mean ± SEM and analyzed by two-tailed Mann-Whitney t test. *p < 0.05, **p < 0.01, and ***p < 0.001.